Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 1 de 1
Filter
Add more filters










Database
Language
Publication year range
1.
In Vivo ; 30(6): 745-749, 2016.
Article in English | MEDLINE | ID: mdl-27815457

ABSTRACT

BACKGROUND/AIM: To study the prevention of chemotherapy resistance, we have previously designed models of drug-resistant ovarian cancer. We here report an in vivo model of cisplatin-resistant small cell lung cancer (SCLC). MATERIALS AND METHODS: Mice bearing H526 SCLC xenografts received intraperitoneal pretreatment with a sub-effective cisplatin dose (0.75-1.5 mg/kg) or no pretreatment (controls). Seven days later, all mice received a higher cisplatin dose (3.0 mg/kg), and tumor response was recorded. Cell cultures initiated from pretreated and control xenografts were tested for cisplatin resistance and for glutathione-S-transferase (GST) activity. RESULTS: Pretreatment with 1.5 mg/kg cisplatin induced resistance to 3.0 mg/kg cisplatin. Cells from a pretreated tumor were cisplatin resistant and had nearly twice the GST activity as cells from a control tumor. CONCLUSION: Such cells may prove useful for identifying other resistance mechanisms and thus guide the selection of potential preventative agents to be tested in the in vivo model.


Subject(s)
Carcinoma, Small Cell/drug therapy , Cisplatin/pharmacology , Drug Resistance, Neoplasm , Lung Neoplasms/drug therapy , Xenograft Model Antitumor Assays , Animals , Antineoplastic Agents/pharmacology , Carcinoma, Small Cell/pathology , Cell Line, Tumor , Dose-Response Relationship, Drug , Humans , Lung Neoplasms/pathology , Mice , Time Factors , Treatment Outcome , Tumor Burden/drug effects
SELECTION OF CITATIONS
SEARCH DETAIL
...